NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.
Two anti-TROP2 ADCs join cell therapies and Teva’s anti-PD-1 in first-in-human studies.
After being burned by Point, Lilly is taking a slower approach with Radionetics.
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
